Pharmacy World & Science

, 30:610 | Cite as

Pulmonary embolism after tadalafil ingestion

  • Huang-Chi ChenEmail author
  • Chuan-Sheng Wang
  • Shu-Hui Chuang
  • Cheng-Yuan Wang
Case Report


Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor that is used to treat male erectile dysfunction. It is currently undergoing clinical trials for the treatment of pulmonary hypertension. Although at present there is no evidence of hypercoagulation states being associated with the use of PDE5 inhibitors, several studies suggest that PDE5 inhibitors may, in rare cases, cause arterial and venous thrombotic or embolic events in the heart, eye, brain, and ear. We report a 54-year-old male patient with reduced plasma levels of protein C who developed pulmonary embolism (PE) just after he started taking tadalafil. The Naranjo probability scale indicates tadalafil as the possible cause of a PE in our patient. To the best of our knowledge, this is the first case report of tadalafil-induced PE in the literature.


Tadalafil Phosphodiesterase inhibitors Pulmonary embolism Adverse effect Erection dysfunction 






Conflicts of Interest



  1. 1.
    Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther. 2007;29:2134–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47–52.PubMedGoogle Scholar
  3. 3.
    Feenstra J, van Drie-Pierik RJ, Laclé CF, Stricker BH. Acute myocardial infarction associated with sildenafil. Lancet. 1998;352:957–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Tripathi A, O’Donnell NP. Branch retinal artery occlusion; another complication of sildenafil. Br J Ophthalmol. 2000;84:934–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Morgan JC, Alhatou M, Oberlies J, Johnston KC. Transient ischemic attack and stroke associated with sildenafil (Viagra) use. Neurology. 2001;57:1730–1.PubMedGoogle Scholar
  6. 6.
    Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol. 2001;21:22–5.PubMedGoogle Scholar
  7. 7.
    Mukherjee B, Shivakumar T. A case of sensorineural deafness following ingestion of sildenafil. J Laryngol Otol. 2007;121:395–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Rufa A, Cerase A, Monti L, Dotti MT, Giorgio A, Sicurelli F, et al. Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction. J Neurol Sci. 2007;260:293–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol. 1999;56:124–30.PubMedGoogle Scholar
  10. 10.
    Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Suppiramaniam V, Dhanasekaran M. Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep. 2007;59:150–63.PubMedGoogle Scholar
  11. 11.
    Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kabrhel C, McAfee AT, Goldhaber SZ. The probability of pulmonary embolism is a function of the diagnoses considered most likely before testing. Acad Emerg Med. 2006;13:471–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C–44C.PubMedCrossRefGoogle Scholar
  14. 14.
    Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract. 2006;60:500–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Huang-Chi Chen
    • 1
    Email author
  • Chuan-Sheng Wang
    • 1
  • Shu-Hui Chuang
    • 2
  • Cheng-Yuan Wang
    • 3
  1. 1.Division of Pulmonary and Critical Care Medicine, Department of Internal MedicineKaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan, ROC
  2. 2.Department of Nursing, Kaohsiung Municipal Hsiao-Kang HospitalKaohsiung Medical UniversityKaohsiungTaiwan, ROC
  3. 3.Division of Pulmonary and Critical Care Medicine, Department of Internal MedicineKaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan, ROC

Personalised recommendations